2237

New Nasal Delivery Technology for Quick-Onset Treatment of Insomnia, Erectile Dysfunction, Pain, Hot Flashes and Other Disorders

Touitou Elka, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research

 

Background

With advances in biotechnology, nasal drug delivery is increasingly becoming a more viable alternative to oral and injectable routes of administration for an increasing number of drugs, including peptides.

Our Innovation

  • Platform for efficient drug therapy by nasal delivery for approved or new drugs, single drugs or combination of drugs (also including new drug combinations). May be used  for the treatment of: CNS related disorders (MS, Insomnia, Sleepiness, Emesis, Parkinson), Hyperglycemias, Erectile Dysfunction, Pain, Hot Flushes and  Obesity.

Key Features

  • Improved delivery into the brain.
  • Better bioavailability by nasal route than by oral or subcutaneous routes.
  • Particularly important in crisis management such as for multiple sclerosis, Alzheimer, insomnia, glioma, sleepiness (EDS), epileptic seizures, hyperglycemia, hypoglycaemia, hot flushes, emesis, Parkinson rigidity
  • Carrier ingredients already have FDA approval for nasal delivery.
  • Increase patient compliance - needle-free alternative for delivering drugs for acute and chronic conditions, allowing self-medication.

Highlights

  • Concept has been proved in animal models (including sheep) for many diseases  and various drugs including large molecules and peptides.
  • Examples: Efficient treatment and disease prevention in EAE mice (drugs: steroids, glatiramer acetate, new drug combinations), antiemetic in rat model (drug: granisetron),  antiwrithing effect (drug: diazepam), malaria prevention and treatment ( drug: DHA   Industrial upscale results already obtained.
  • Planned Phase I and Phase II trials.
  • Prior FDA ingredient approvals will lead to faster product approval process.

 The Opportunity

 Seeking investment and cooperation for ongoing development of a number of drugs.

Contact for more information:

Shani Bullock
VP, Business Development, Healthcare
+972-2-6586608
Contact ME: